ReviewPlants (Basel, Switzerland)2026
Single-Cell Insights into Medicinal Plant Development and Metabolism.
Review in Plants (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medicinal plants are major sources of therapeutic natural products, yet the cell-type-specific organization that governs metabolite biosynthesis, transport, and storage remains imperfectly resolved by organ-level omics. This review synthesizes studies published up to June 2026 that used single-cell, single-nucleus, spatial, metabolomic, and epigenomic approaches to medicinal plant systems, following a PRISMA-guided literature search across PubMed, Web of Science, Scopus, and CNKI. Emerging evidence shows that specialized metabolism is organized through discrete and often rare cell populations, including idioblasts, laticifers, glandular trichomes, secretory epidermal cells, internal phloem-associated parenchyma, cork and periderm cells, mesophyll cells, and other biosynthetic niches. Single-cell RNA sequencing has defined these populations and reconstructed developmental trajectories, whereas single-cell metabolomics and mass spectrometry imaging reveal that metabolite accumulation frequently diverges from biosynthetic gene expression because of intercellular transport, storage capacity, and subcellular compartmentation. Single-cell ATAC-seq and multiome profiling further identify cell-type-specific regulatory regions, transcription factors, and candidate promoters controlling metabolic competence. Together, these technologies are reshaping medicinal plant biology from pathway-centric catalogs into spatially and developmentally resolved cellular maps. We highlight how artificial intelligence (AI)-assisted integration can accelerate cell annotation, regulatory network inference, metabolite assignment, and prioritization of biosynthetic genes, transporters, and engineering targets. Future progress will depend on comparative medicinal plant atlases, improved recovery of recalcitrant tissues, matched transcriptomic, metabolomic, and spatial designs, and functional validation of cell-type-specific mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.